



## Outsourcing in Clinical Trials Europe

Barcelona, Spain

3<sup>rd</sup> & 4<sup>th</sup> May 2023 www.arena-international.com/octeurope

'This event will focus on optimizing strategies to create an operationally efficient, specifically targeted clinical trial'

For the 13th Annual event, our flagship European clinical show will focus on providing delegates with practical takeaways and solutions to their most current operational and outsourcing challenges in clinical trials, this is an event not to be missed.

#### **2023 Confirmed Speakers**

- Roman Fishchuk, Head of Clinical Trials
   Department, Central City Clinical Hospital,
   Ukraine
- Mariusz Olejniczak, CEO, WPD Pharmaceuticals
- Sonja Weiser, Senior Director Clinical Operations, Insmed
- Marco Salami, Head of Clinical & RWE Outsourcing Management, Chiesi Farmaceutici
- Werner Gladdines, VP, Clinical Development
   Operations, Immunic Therapeutics
- Ivanna Rosendal, Senior Director, IT Business
   Partner, Ascendis Pharma
- Ivan Vyshnivetskyy, President, Ukrainian
   Association for Clinical Research
- Estrella Garcia, Senior Director Global Clinical Operations, Almirall
- Silvia Perez Torres, Director, Clinical Quality
   Compliance, AstraZeneca
- Roel van der Heijde, Facilitator & Trainer, Patient
   Experience Association
- Daniel McVeigh, Director, Clinical Project Lead , Alexion
- Benoît Marchal, Chief Digital Trust Officer, Partners for Patients, PicAps (NFP)
- Laia Casas, Clinical Project Leader, Noucor Health
   SA
- Priya Nair, Senior Analyst, GlobalData
- Robert S. Greene, President, Hunger and Thirst
   Foundation
- Michael Zörer, Head of Clinical Operations, VarmX

- Domenico Merante, Therapeutic Area Clinical Lead Nephrology, Rare and Orphan Diseases, CSL Vifor
- Xavi Jofre, Digital Transformation Director, Barcelona
   Health Hub
- Henrik Schou, VP, Global Head Evidence Generation, Vifor Pharma Group
- Begoña Nafria Escalera, Patient Engagement & Research Coordinator, Sant Joan de Deu Barcelona Hospital
- James Rudge, Technical Director, Trajan Scientific and Medical
- Balint Feher, Senior Clinical Research Manager, Geistlich Pharma AG
- Stephen Lutsch, Former Director Revolutionize Clinical Trials (ReCT), LEO Pharma
- Joana Claverol, Clinical Research Unit Manager, Sant Joan de Deu Barcelona Hospital
- Jelena Mihajlović, Clinical Operations Program Lead, Immunic Therapeutics
- Laura Jiménez Robledo, Clinical Project and Innovation Manager, Novo Nordisk
- Smruthi Panyam, Director, Clinical Data Informatics, BeiGene
- Elena Carzana, Vendors Alliance Manager DM&Stat, Chiesi Farmaceutici
- Anna Pugnetti, Global Clinical and RWE Outsourcing Manager, Chiesi Farmaceutici
- John Zibert, Chief Medical Officer, Coegin Pharma AB
- Stefania Alvino, Digital Orchestrator & Omnichannel Marketing Manager, **Daiichi Sankyo**

Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: <u>NicholasMcCudden@arena-</u> international.com

# Outsourcing in Clinical Trials Europe 3rd-4th May 2023

### DAY ONE - WEDNESDAY 3RD MAY 2023

| 08:20       Chair's opening remarks<br>Chair: Robert S. Greene, President, Hunger and Thirst Foundation         08:20       KEYNOTE<br>Disaster Preparedness: How can the clinical trial industry prepare for the unexpected? Using the<br>Ukrainian crisis as a case study         08:30       Briefly explaining the impact of the war on Ukraine's/Europe's clinical trial industry         08:30       Involving sites with sponsor decisions when developing Decentralized models – what tech and<br>solutions can sites offer?         1       Identifying what protocol changes help sites vs what makes their job harder         08:30       A message to Ukrainian Pharma offices: Importance of backup plans to ensure data integrity and<br>keep trials moving         08:01       New solutions – bringing in a reliable Ukrainian CRO with local knowledge to work directly with trial<br>sponsors         Roman Fishchuk, Head of Clinical trials department, Central City Clinical Hospital, Ukraine         09:00       Session Reserved for Medidata         INTERACTIVE SESSION<br>The Diversity Conversation – follow up from the 2022 discussion and what we should do for 2023<br>and beyond         This session will cover diversity and race inequalities in clinical trials; why we have underrepresentation<br>and why it's vital we improve. Robert & Roel will give an overview and then open up the discussion to the<br>audience;         • Exploring what diversity means in clinical trials – what have we done to improve this since the 2022<br>event?         • How can we improve engagement by paying more of a focus on race and socioeconomic disparities? | 07:45 | Conference registration and refreshments   |
|---|-------|--|
| Disaster Preparedness: How can the clinical trial industry prepare for the unexpected? Using the Ukrainian crisis as a case study         • Briefly explaining the impact of the war on Ukraine's/Europe's clinical trial industry         • Involving sites with sponsor decisions when developing Decentralized models – what tech and solutions can sites offer?         • Identifying what protocol changes help sites vs what makes their job harder         • A message to Ukrainian Pharma offices: Importance of backup plans to ensure data integrity and keep trials moving         • Mitigation risk plans: Making plans for the future and involving all clinical trial stakeholders         • New solutions – bringing in a reliable Ukrainian CRO with local knowledge to work directly with trial sponsors <i>Roman Fishchuk, Head of Clinical trials department, Central City Clinical Hospital, Ukraine</i> 09:00       Session Reserved for Medidata         INTERACTIVE SESSION         The Diversity Conversation – follow up from the 2022 discussion and what we should do for 2023 and beyond         This session will cover diversity and race inequalities in clinical trials; why we have underrepresentation and why it's vital we improve. Robert & Roel will give an overview and then open up the discussion to the audience;         • Exploring what diversity means in clinical trials – what have we done to improve this since the 2022 event?         09:30       How can we improve engagement by paying more of a focus on race and socioeconomic disparities?         • Exploring the role of patient advocacy groups in tackling underreprese            | 08:20 |  |
| INTERACTIVE SESSION<br>The Diversity Conversation – follow up from the 2022 discussion and what we should do for 2023<br>and beyondThis session will cover diversity and race inequalities in clinical trials; why we have underrepresentation<br>and why it's vital we improve. Robert & Roel will give an overview and then open up the discussion to the<br>audience;09:30Exploring what diversity means in clinical trials – what have we done to improve this since the 2022<br>event?09:30How can we improve engagement by paying more of a focus on race and socioeconomic disparities?<br>Exploring the role of patient advocacy groups in tackling underrepresentation<br>Highlighting the impact on your trial if all groups aren't adequately represented – ask ourselves why<br>not<br>Brainstorming solutions: What actions can we take now to get groups interested in participating in<br>trials?<br>Audience stories, feedback and strategies moving forward<br>Robert S. Greene, President, Hunger and Thirst Foundation &<br>Roel van der Heijde, Facilitator & Trainer, Roel Rotterdam & Patient Experience Association10:00Session Reserved for Featured Sponsor  | 08:30 | <ul> <li>Disaster Preparedness: How can the clinical trial industry prepare for the unexpected? Using the Ukrainian crisis as a case study</li> <li>Briefly explaining the impact of the war on Ukraine's/Europe's clinical trial industry</li> <li>Involving sites with sponsor decisions when developing Decentralized models – what tech and solutions can sites offer?</li> <li>Identifying what protocol changes help sites vs what makes their job harder</li> <li>A message to Ukrainian Pharma offices: Importance of backup plans to ensure data integrity and keep trials moving</li> <li>Mitigation risk plans: Making plans for the future and involving all clinical trial stakeholders</li> <li>New solutions – bringing in a reliable Ukrainian CRO with local knowledge to work directly with trial sponsors</li> </ul>  |
| The Diversity Conversation – follow up from the 2022 discussion and what we should do for 2023<br>and beyondThis session will cover diversity and race inequalities in clinical trials; why we have underrepresentation<br>and why it's vital we improve. Robert & Roel will give an overview and then open up the discussion to the<br>audience;09:30Exploring what diversity means in clinical trials – what have we done to improve this since the 2022<br>event?09:30How can we improve engagement by paying more of a focus on race and socioeconomic disparities?<br>• Exploring the role of patient advocacy groups in tackling underrepresentation<br>• Highlighting the impact on your trial if all groups aren't adequately represented – ask ourselves why<br>not<br>• Brainstorming solutions: What actions can we take now to get groups interested in participating in<br>trials?<br>• Audience stories, feedback and strategies moving forward<br>Robert S. Greene, President, Hunger and Thirst Foundation &<br>Roel van der Heijde, Facilitator & Trainer, Roel Rotterdam & Patient Experience Association10:00Session Reserved for Featured Sponsor   | 09:00 | Session Reserved for Medidata  |
|   | 09:30 | <ul> <li>The Diversity Conversation – follow up from the 2022 discussion and what we should do for 2023 and beyond</li> <li>This session will cover diversity and race inequalities in clinical trials; why we have underrepresentation and why it's vital we improve. Robert &amp; Roel will give an overview and then open up the discussion to the audience;</li> <li>Exploring what diversity means in clinical trials – what have we done to improve this since the 2022 event?</li> <li>How can we improve engagement by paying more of a focus on race and socioeconomic disparities?</li> <li>Exploring the role of patient advocacy groups in tackling underrepresentation</li> <li>Highlighting the impact on your trial if all groups aren't adequately represented – ask ourselves why not</li> <li>Brainstorming solutions: What actions can we take now to get groups interested in participating in trials?</li> <li>Audience stories, feedback and strategies moving forward</li> <li>Robert S. Greene, President, Hunger and Thirst Foundation &amp;</li> </ul> |
| 10:30   | 10:00 | Session Reserved for Featured Sponsor  |
|   | 10:30 |  |

REGISTER HERE

Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: <u>NicholasMcCudden@arena-</u> international.com

|                   | Morning refreshments and networking  |  |   |
|-------------------|--|--|---|
|                   | Stream A:<br>Outsourcing & Clinical<br>Operations<br>Chair: Robert S. Greene,<br>President, Hunger and Thirst<br>Foundation  | Stream B:<br>Clinical Technology &<br>Innovation<br>Chair: Priya Nair, Senior<br>Analyst, GlobalData   | Stream C:<br>Clinical Data; Strategy &<br>Planning<br>Chair: Roel van der Heijde,<br>Facilitator & Trainer, Roel<br>Rotterdam & Patient<br>Experience Association   |
|                   | PANEL DISCUSSION   | PANEL DISCUSSION PANEL   |   |
| PANEL<br>SCUSSION | Handling prolonged site start-<br>up times and the worldwide site<br>staff shortages crisis  | Key considerations for<br>designing and implementing<br>DCTs; exploring the protocol   | CASE STUDY<br>Data Access vs Data Privacy.<br>Would the simplest not be to<br>ask the patients themselves?  |
| 11:00             | <ul> <li>Pinpointing the challenges of getting all vendors/systems in place for study start-up –is this beyond the site's capacity?</li> <li>Encouraging all stakeholders to take time and get involved in budget negotiation to reduce site activation delays</li> <li>With complexity of trials increasing, what affect will this have on site staff training?</li> <li>Importance of easy access to training particularly when site staff is low – can vendors help?</li> <li>Sharing ideas for retaining site staff/physician talent in the industry</li> <li>Could flying study nurses help in the short term?</li> </ul> Moderator: Robert S. Greene, President, Hunger and Thirst Foundation Panellists: Sonja Weiser, Senior Director Clinical Operations, Insmed; Roman Fishchuk, Head of Clinical trials department, Central City Clinical Hospital, Ukraine; Ivan Vyshnivetskyy, President, Ukrainian Association for Clinical Research | <ul> <li>design</li> <li>Exploring the idea that DCT is not a one-size-fits-all approach</li> <li>Looking to outsource if you lack internal capabilities to operationalize DCT</li> <li>Designing a proactive strategy with patient groups to maximize efficiency and the patient experience</li> <li>Considering a hybrid trial as a more agile design</li> <li>Importance of engaging with regulatory agencies early</li> <li>Using the knowledge of traditional sites – how to work with a combination of physical and remote sites for protocol design</li> <li>Explore user testing and involvement when going digital</li> <li>Moderator: Priya Nair, Senior Analyst, GlobalData</li> <li>Panellists: John Zibert, Chief Medical Officer, Coegin Pharma AB;</li> <li>Stephen Lutsch, Former Director - Revolutionize Clinical Trials (ReCT), LEO Pharma</li> </ul> | In this talk Benoît will introduce<br>PicAps (Patient in Control,<br>Anonymity Privacy Secured) and<br>explore the benefits of a direct<br>anonymous communication with<br>the patients.<br>• For what? Clinical trials<br>use cases: Lay<br>summaries,<br>Recruitment, Clinical trial<br>data sharing, long time<br>follow-up, home<br>delivery, continuous<br>monitoring<br>• How it works:<br>decentralized network of<br>trusted neutral<br>organizations to ensure<br>privacy<br>• Regulatory aspect<br>• The big picture: access to<br>EHR data<br>Benoît Marchal, Chief Digital<br>Trust Officer, Partners for<br>Patients, PicAps |
| 11:45             | Session Reserved for Event<br>Sponsor  | Session Reserved for Event<br>Sponsor  | Session Reserved for Event<br>Sponsor   |

Stand and

Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: <u>NicholasMcCudden@arena-</u> international.com

1.24

|  | 12:15                      | <ul> <li>CASE STUDY<br/>Stop taking the easy route!<br/>Delving into recent societal<br/>changes and how Clinical Trials<br/>can adapt</li> <li>Appreciating the need to be<br/>more inclusive with race but<br/>what about other<br/>underrepresented groups?</li> <li>Discussing the use of male vs<br/>female in ICFs and<br/>inclusion/exclusion criteria –<br/>impact of not including<br/>LGBTQ+</li> <li>Exploring the benefits of<br/>updating your ICF to adapt to<br/>societal changes and linguistic<br/>challenges</li> <li>Best practices for engaging<br/>with ethics committees and<br/>coming to an agreement on<br/>terms</li> <li>Examples of getting wording<br/>approved by ethics committee<br/>– get hands on today!</li> <li>Laia Casas, Clinical Project<br/>Leader, Noucor Health SA</li> </ul> | <section-header></section-header>  | <ul> <li>Exploring how to use data collected through consumer-wearables and integrate them into a clinical trial</li> <li>How to integrate data collected through consumer-wearables into a clinical trial</li> <li>Why consumer-wearables can provide wider access to clinical trials</li> <li>Consumer wearables and data that they can reliably collect</li> <li>Getting data from the wearables to contribute to the clinical trial</li> <li><i>Ivanna Rosendal, Senior Director, IT Business Partner, Ascendis Pharma</i></li> </ul> |
|--|----------------------------|--|--|---|
|  | 12:45                      | Session Reserved for Event<br>Sponsor  | Session Reserved for Event<br>Sponsor  | Session Reserved for Event<br>Sponsor   |
|  | 13:15 Lunch and networking |  |  |   |
| and the second s | 14:15                      | Call for research in creative<br>climate in organization in<br>clinical development<br>Mariusz will explore his research<br>and discovery on how to help<br>CRO and pharma to be more<br>productive<br>Mariusz Olejniczak, CEO, WPD<br>Pharmaceuticlas   | <ul> <li>2023 UPDATE: Sharing<br/>practical experiences with<br/>Decentralized &amp; Hybrid Trials –<br/>is there a future for DCT?</li> <li>Advantages of DCT; from<br/>taking the trial to the patient<br/>boosting recruitment</li> <li>The benefits and constraints<br/>of DCT based on practical<br/>experience from running DCT</li> <li>Learnings from an inspection<br/>of an interventional DCT -<br/>what is the role of the<br/>patient?</li> <li>Strategy/Planning: How do<br/>you make the decision to run<br/>a DCT; what are the<br/>considerations?</li> <li>Is the future hybrid trials as<br/>they are more realistic and</li> </ul> | Utilizing Data Mesh<br>technologies for data analysis<br>in clinical trials<br>Bullets to come<br>Mateusz Zabolski, Head of<br>Technology – Biosamples,<br>AstraZeneca<br>& colleague   |

Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: <u>NicholasMcCudden@arena-</u> international.com

1.34

L'AL

|       |   | practical compared to full<br>DCT?<br>John Zibert, Chief Medical<br>Officer, Coegin Pharma AB  |  |
|-------|---|--|--|
| 14:45 | Session Reserved for Event<br>Sponsor   | Session Reserved for Event<br>Sponsor  | Session Reserved for Event<br>Sponsor  |
| 15:15 |   | Communication & Innovation:<br>Defining innovation in clinical<br>trials<br>• What is innovation in<br>clinical trials?<br>• Why communication is key<br>in our innovation strategy?<br>• How do we communicate<br>innovation?<br>Laura Jiménez Robledo,<br>Clinical Project and Innovation<br>Manager, Novo Nordisk   | <ul> <li>The rise of RWE/RWD:<br/>Unlocking how to properly<br/>utilize real world evidence to<br/>improve study design and<br/>execution</li> <li>Sharing positive<br/>experiences of<br/>supplementing clinical tri<br/>data with RWD/RWE</li> <li>Navigating RWE to gain<br/>metrics on how many<br/>patients sites bring in to<br/>improve site selection</li> <li>Utilizing RWE in a non-<br/>international study to loo<br/>into desired factors</li> <li>RWE allowing a better<br/>understanding of unmet<br/>need and<br/>unrepresentativeness- ho<br/>can this benefit physiciar<br/>and patient?</li> <li>Regulatory landscape ist<br/>giving many clues – wha<br/>are regulators saying any<br/>how should we approach<br/>it?</li> <li>Smruthi Panyam, Director,<br/>Clinical Data Informatics,<br/>BeiGene</li> </ul> |
| 15:45 | 5 Afternoon refreshments and networking   |  |  |
| 16:15 | Session Reserved for Event<br>Sponsor   | Session Reserved for Event Sponsor   |  |
| 16:45 | <ul> <li>Pro et contra of working with<br/>Professional Site Networks for<br/>sponsors and CROs</li> <li>Does the industry needs<br/>professionalization of clinical<br/>research sites?</li> </ul> | <ul> <li>Paediatric-centric clinical trials: A right for children and young people</li> <li>Children's rights in their involvement in clinical research</li> <li>Why? Who? Where? Involve children and young people</li> <li>Return on the investment and return on the engagement</li> <li>eYPAGnet: European Network of Young Person's Advisory Groups Network</li> <li>Case study: DCT in paediatric clinical trials</li> </ul> |  |

- and the second

Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: <u>NicholasMcCudden@arena-</u> international.com

8.24

| 4               | 7     |   |   |
|-----------------|-------|---|---|
| Statistical Man | R.    | <ul> <li>The general perception of site networks and site management organizations</li> <li>What benefits can professional site networks provide to sponsors and CROs</li> <li>Risks and drawbacks of working with Professional Site Networks</li> <li>Ivan Vyshnivetskyy, President, Ukrainian Association for Clinical Research</li> </ul>  | Begoña Nafria Escalera, Patient Engagement & Research<br>Coordinator, Sant Joan de Deu Barcelona Hospital<br>Joana Claverol, Clinical Research Unit Manager, Sant Joan de Deu<br>Barcelona Hospital   |
|                 | 17:15 | Clinical Research CLOSING KEYNOTE Can the new EU Clinical Trial Regulation revolutionize clinical trial processes across Europe, creating a more streamlined application? Gain a comprehensive overview of the EU Clinical Trial Regulation and changes for trials in the EU Benefits of submitting through same portal for all ethics committees/authorities The advantages for biopharma companies of standardized timelines Understanding the new trial authorisation process for regulatory and ethical approval Understanding the new trial authorisation process for regulatory and ethical approval Overview of major new requirements, such as risk- based evaluations and informed consent Update since January 2023 Reserved for Sermes CRO & biopharma | CLOSING KEYNOTE Decentralized Clinical Trials/Hybrid Trials: Lessons learned and what you need to know to run them successfully  Delving into the promise of DCT Laying the innovation and technical foundation for DCT My key learnings from running DCT/hybrid trials Tangible takeaways Stephen Lutsch, Former Director - Revolutionize Clinical Trials (ReCT), LEO Pharma |
|                 | 17:45 | Chair's Summary & Drinks Receptio   | n   |

### DAY TWO – THURSDAY 4<sup>TH</sup> MAY 2023

|    | 08:10 | Registration and refreshments |
|----|-------|-------------------------------|
| 12 | 08:45 |                               |

REGISTER HERE

Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: NicholasMcCudden@arenainternational.com

|  | Chair's opening remaind | arks |  |
|--|-------------------------|------|--|
|--|-------------------------|------|--|

|       | Stream A:<br>Outsourcing & Clinical Operations<br>Chair: Werner Gladdines, VP, Clinical<br>Development Operations, Immunic<br>Therapeutics  | Stream B:<br>Clinical Technology & Innovation<br>Chair: Priya Nair, Senior Analyst, GlobalData   |
|-------|---|--|
|       | PANEL DISCUSSION  | WORKSHOP   |
| 09:00 | <ul> <li>Reversing the Conversation: What the clinical trial industry really wants from its service providers</li> <li>We've all had to sit through pitches from vendor companies telling us what they can do for us, but now it's time to reverse the conversation! Hear from the trial industry as they discuss the services they would like to see from their solution providers, including: <ul> <li>What they like to see in an outsourced partner organization</li> <li>What they would like a partner to know about them / how they work</li> <li>What things do they need a partner to do and what they don't need!</li> <li>What things can be best done in house?</li> </ul> </li> <li>Moderator: Werner Gladdines, VP, Clinical Development Operations, Immunic Therapeutics <ul> <li>Panellists: Sonja Weiser, Senior Director Clinical Operations, Insmed;</li> <li>Daniel Mc Veigh, Director, Clinical Project Lead, Alexion;</li> <li>Michael Zörer, Head of Clinical Operations, VarmX</li> </ul> </li> </ul> | Introducing The Patient Centric Sample Interest<br>Group<br>This workshop will explore different approaches and<br>strategies for putting patients at the centre when<br>collecting samples for clinical trials<br>James Rudge, Technical Director, Trajan Scientific<br>and Medical   |
| 09:45 | Session Reserved for Event Sponsor  | Session Reserved for Event Sponsor   |
| 10:15 | <ul> <li>FIRESIDE CHAT</li> <li>Establishing strong CRO/sponsor<br/>relationships and building trust in a more<br/>virtual landscape- What 5 things does our<br/>expert speaker say to focus on right now?</li> <li>Oversight with less presence- designing<br/>an oversight plan based on KPIs, fewer<br/>monitoring visits and more virtual<br/>meetings, how to make this work</li> <li>Lessons learned on how to effectively build<br/>working relationships remotely</li> <li>Strategies to deliver training and upskill<br/>your clinical trial team</li> <li>Handling hard discussions with the site<br/>remotely if can't get there in person</li> </ul>  | <ul> <li>Case study: Clinical digitalization roadmap for medical device companies</li> <li>Outlining the specific digital transformation goals and requirements</li> <li>Overcoming operational challenges associated with medium-sized medical device companies</li> <li>Journey to successful clinical digitalization</li> </ul> Balint Feher, Senior Clinical Research Manager, Geistlich Pharma AG |

Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: <u>NicholasMcCudden@arena-</u> international.com

| North De |       | <ul> <li>Guidance on improving CRO<br/>communication channels– keep CROs in<br/>the loop and draw on their experience</li> <li>We are all human, we all fail: Ensuring<br/>positivity in initial stages and taking<br/>responsibility</li> <li>Moderator: Werner Gladdines, VP, Clinical<br/>Development Operations, Immunic<br/>Therapeutics</li> <li>Marco Salami, Head of Clinical &amp; RWE<br/>Outsourcing Management, Chiesi Farmaceutici</li> </ul>  |  |
|----------|-------|---|--|
| 1919     | 10:45 | Session Reserved for Event Sponsor  | Session Reserved for Event Sponsor   |
| - Tarter | 11:15 | Morning refreshments and networking   |  |
|          | 11:45 | <ul> <li>Optimizing oversight &amp; governance: What does oversight mean to you?</li> <li>Best practices and tools for managing supplier governance and ascertaining who is accountable</li> <li>Identifying the criteria to determine level of oversight needed for a vendor</li> <li>Local vendor oversight vs global provider oversight – how would you manage this differently?</li> <li>Strategies for managing CRO governance for small/start-up companies with limited resources or large companies with competing priorities</li> <li>Daniel McVeigh, Director, Clinical Project Lead, Alexion</li> </ul> | <ul> <li>Bridging the gap from RCTs through Real World Evidence into clinical practice; exploring how to improve patient focussed disease management</li> <li>Relevance of generating Real World Evidence data in rare ad orphan kidney diseases</li> <li>The urgent need to access main clinical data, including those from still unpublished clinical studies</li> <li>Bridging an existing gap between randomized clinical trials results and clinical practice evidence for people affected by rare and orphan kidney diseases</li> <li>Development of 'personalized' treatment algorithms to improve patient-focused outcomes in patients suffering from these diseases</li> <li>Domenico Merante, Therapeutic Area Clinical Lead Nephrology, Rare and Orphan Diseases, CSL Vifor</li> <li>Henrik Schou, VP, Global Head Evidence Generation, Vifor Pharma Group</li> </ul> |
|          | 12:15 | Session Reserved for Event Sponsor  | Session Reserved for Event Sponsor   |
|          | 12:45 | <ul> <li>Exploring the role of Quality in vendor oversight and vendor quality agreements</li> <li>How can Quality provide more support to the study team, particularly with vendor oversight?</li> <li>Exploring the importance of quality agreements and vendor communications – how can we add more value with monitoring/safety aspects?</li> <li>Best practices in reporting to ensure patience safety and preventative action</li> </ul>   | Innovation topic TBC<br>Stefania Alvino, Digital Orchestrator & Omnichannel<br>Marketing Manager, Daiichi Sankyo   |

No. of Contraction

Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: <u>NicholasMcCudden@arena-</u> international.com

. 2.2.4

| R     | <ul> <li>How can Quality work more closely with regulatory bodies on reporting issues to ensure GCP?</li> <li>Exploring risk-based quality management strategies</li> <li>Silvia Perez Torres, Director, Clinical Quality Compliance, Astrazeneca</li> </ul>   |  |
|-------|--|--|
| 13:15 | Lunch and networking and Apple Prize draw  |  |
| 14:15 | Session Reserved for Event Sponsor   | Session Reserved for Event Sponsor   |
| 14:45 | <ul> <li>The current impact and future of Decentralized Clinical Trials</li> <li>The impact of COVID-19 on the future of clinical trials and the main concern for primary sponsors and CRO's during the COVID-19 pandemic</li> <li>The movement towards DCT's and why sponsors are incorporating digital elements into clinical trials and the challenges around this</li> <li>How AI can aid decentralized trials and real-life case studies</li> <li>Priya Nair, Senior Analyst, GlobalData</li> </ul>               | INTERACTIVE THINK TANKS<br>Interactive think tank sessions offer a unique<br>opportunity to come together to share best practice<br>and develop solutions to challenges facing the<br>industry as a whole. Hosted by industry experts and<br>each focused on a single issue, think tanks are an<br>interactive way to build your personal network and<br>learn from the experience of others.<br>Each think tank session lasts for 30 minutes, and<br>delegates may attend up to 2<br>Think Tank 1: What does the clinical trial industry<br>really want from its service providers?<br>Host: Estrella Garcia, Senior Director Global Clinical<br>Operations, Almirall |
| 15:15 | <ul> <li>TBC TOPIC</li> <li>Choosing a CRO as a small to mid-sized biotech company: factors to consider</li> <li>Balancing the benefits of working with a small CRO vs a large global CRO: which is better equipped to handle the needs of a smaller biotech?</li> <li>How important is it to choose a CRO with experience in your therapeutic area?</li> <li>Working with multiple vendors: is this the best option for smaller sponsor companies?</li> <li>Jelena Mihajlović, Clinical Operations Program</li> </ul> | Think Tank 2: Building strategic partnerships with CROs         Host: Elena Carzana, Vendors Alliance Manager         DM&Stat, Chiesi Farmaceutici         & Anna Pugnetti, Global Clinical and RWE         Outsourcing Manager, Chiesi Farmaceutici         Think Tank 3: Working with Patient Advocacy         Groups & overcoming barriers with patient         engagement         Host:  |
| 2000  | Lead, Immunic Therapeutics   |  |

No. Con

Sales Enquiry Nicholas McCudden Head of Sponsorship Sales T: +44 (0)207 9472755 E: <u>NicholasMcCudden@arena-</u> international.com

8.34